Celcuity Inc. (CELC) company profile
Close on Nov 12, 2026Market cap $3.14BP/E –Yield –
About Celcuity
Services-Medical Laboratories, SIC 8071
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies to treat various solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor targeting class I PI3K isoforms and mTOR complexes (mTORC1 and mTORC2) to achieve comprehensive inhibition of the PAM signaling pathway. The company is evaluating this candidate in clinical studies primarily for patients with advanced breast cancer and metastatic castration-resistant prostate cancer who have experienced disease progression on prior standard therapies.
Celcuity conducts clinical research across a global footprint, including expected participation from roughly 200 clinical study sites spanning North America, Europe, and the Asia-Pacific region. Incorporated in Delaware, the company maintains its principal executive offices and headquarters in Minneapolis, Minnesota.
Summary of the business section of Celcuity's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Celcuity Inc.
- Headquarters
- Minneapolis, MN
- Address
- 16305 36th Avenue N, Suite 100 55446
- Phone
- (763) 392-0767
- Website
- celcuity.com
- Employees
- 155, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Boulay LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- CELC
- Exchange
- Nasdaq
- IPO date
- Sep 20, 2017
- Shares outstanding
- 49M, Aug 5, 2026
- Public float
- $457.49M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1603454
- CUSIP
- 15102K100
- ISIN
- US15102K1007
- FIGI
- BBG00HKBW045
- Share class FIGI
- BBG00HKBW054
- LEI
- 25490070W7UU7W2SEY87
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian F. Sullivan | Chief Executive Officer, Director | 3,200,983 |
| Lance G. Laing | Chief Science Officer, Director | 1,271,000 |
| Vicky Hahne | Chief Financial Officer | 37,808 |
| Leo Furcht | Director | 12,780 |
| David W. Gryska | Director | 893 |
| Polly A. Murphy | Director | 6,530 |
| Richard E. Buller | Director | 9,319 |
| Charles R. Romp | Director | 1,745 |
| Richard Nigon | Director | 100,865 |
| David Dalvey | Director | 66,530 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $16.37M | $63.04M | $3.80M | $712 | – |
| FY2024 | $6.59M | $5.20M | $1.53M | $93 | – |
| FY2023 | $1.74M | $2.46M | $1.19M | $104 | – |
| FY2022 | $1.81M | $2.49M | $599.44K | $106 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| Brian F. Sullivan Chairman and Chief Executive Officer | $577.10K | $15.43M | $368.12K | $16.37M | +149% |
| Lance G. Laing Chief Science Officer | $472.56K | $3.52M | $201.22K | $4.19M | +146% |
| Vicky Hahne Chief Financial Officer | $419.60K | $2.81M | $178.48K | $3.41M | +152% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 20, 2017
- Offer price
- $9.50
- Securities offered
- 2,400,000
- Gross proceeds
- $22.80M
- Exchange
- Nasdaq
- First trading day
- Sep 20, 2017
- First-day close
- $14.29+50.4%
- Lock-up ends (est.)
- Mar 19, 2018
“The initial public offering price is $9.50 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 155 full-time employees, most of which were engaged in research and development activities, though hiring”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 20, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 15, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 15, 2017 | Name change | Name changed from Celcuity LLC to Celcuity Inc. |
See a number that looks wrong?